LeapFinancial | $3,500,000 | (Dec 20, 2024)
TG0 | $5,619,170 | (Dec 20, 2024)
Mindgard | $8,000,000 | (Dec 20, 2024)
Shift Bioscience
United Kingdom
- Cambridge, Cambridgeshire
- 16/10/2024
- Seed
- $16,000,000
Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of ageing. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high throughput and high accuracy aging biomarker, which has been leveraged inside AI-based cell simulations to identify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes the norm.
- Industry Biotechnology Research
- Website https://www.shiftbioscience.com/
- LinkedIn https://www.linkedin.com/company/shiftbioscience/
Related People
Daniel IvesFounder
United Kingdom -
ND
I received my PhD from the University of Cambridge where I focused on the role of mutations in the mitochondrial genome in rare diseases, embracing computational biology to discover a novel therapeutic approach. In 2017 I founded Shift Bioscience and since then, I've been on a scientific journey from mitochondria to mouse aging clocks to single-cell aging clocks and, finally, to now: leveraging single-cell aging clocks inside cell simulations to discover safer interventions for cell rejuvenation.
ŌURA | $200,000,000 | (Dec 20, 2024)
Buildpeer | $2,500,000 | (Dec 20, 2024)
Embeddable | $6,238,050 | (Dec 20, 2024)
Tenor | $5,400,000 | (Dec 20, 2024)
SOTELIX Endoscopy | $1,700,000 | (Dec 20, 2024)
Double(US) | $3,900,000 | (Dec 20, 2024)
Hauler Hero | $10,000,000 | (Dec 20, 2024)
TripSuite | $5,000,000 | (Dec 20, 2024)
Seekho | $8,000,000 | (Dec 19, 2024)